Morbidity and mortality from COVID-19 post-vaccination breakthrough infections in association with vaccines and the emergence of variants in Bahrain

  title={Morbidity and mortality from COVID-19 post-vaccination breakthrough infections in association with vaccines and the emergence of variants in Bahrain},
  author={Manaf Alqahtani and Sujoy Bhattacharyya and Abdulla Alawadi and Hamad Al Mahmeed and Jaleela Al Sayed and Jessica Justman and Wafaa M El-Sadr and Jack D. Hidary and Siddhartha Mukherjee},
The emergence of new SARS-CoV-2 variants across the world has raised concerns about the effectiveness of available COVID-19 vaccines that were designed against the original Wuhan (wild type) variant. Critical questions have arisen regarding: (a) the effectiveness of various vaccines in preventing infection, symptomatic disease, hospitalization, intensive care unit (ICU) admission and death and (b) the magnitude and clinical consequences of post-vaccination infections in the context of… 

Figures and Tables from this paper

The Effect of COVID-19 Vaccination on Reducing the Risk of Infection, Hospitalization, and Death in Isfahan Province, Iran

The highest and lowest reduction in relative risk was for those who received AstraZeneca and Sputnik, respectively.

Literature screening report COVID-19 vaccines and post-vaccination data: Literature update (14)

This report addresses the latest data on the newly identified variant of concern (VOC) Omicron, vaccine effectiveness, booster doses, children vaccination, and new COVID-19 vaccine candidates.

Covid-19: virology, variants, and vaccines

The genetics, structure, and transmission methods of SARS-CoV-2 and its variants are discussed, highlighting how mutations provide enhanced abilities to spread and inflict disease.

Assessment of Clinical Profile and Treatment Outcome in Vaccinated and Unvaccinated SARS-CoV-2 Infected Patients

Results reaffirm the vaccine’s effectiveness in reducing case fatality and promoting faster recovery compared to nonvaccinated patients and efforts to increase the number of immunized subjects in the community help to achieve herd immunity.

Direct comparison of antibody responses to four SARS-CoV-2 vaccines in Mongolia

Functional antibody testing with a panel of nine SARS-CoV-2 viral variant receptor binding domain (RBD) proteins reveal marked differences in vaccine responses, with low antibody levels and RBD-ACE2 blocking activity stimulated by the Sinopharm and Sputnik V vaccines in comparison to the AstraZeneca or Pfizer/BioNTech vaccines.

Statement on the third dose of COVID-19 vaccines ( 16 / 09 / 2021 )

The Delta variant has magnified the non-sterilizing nature of COVID-19 vaccines, revealing their dicotomic behavior, i.e. a waning effectiveness against SARS-CoV-2 infection but a sustained and high effectiviness against the development of severe disease and death.

Factors associated with neutralizing antibody levels induced by two inactivated COVID-19 vaccines for 12 months after primary series vaccination

Background BBIBP-CorV and CoronaVac inactivated COVID-19 vaccines are widely-used, World Health Organization-emergency-listed vaccines. Understanding antibody level changes over time after

Sputnik V Effectiveness against Hospitalization with COVID-19 during Omicron Dominance

The present study indicates the high protective efficacy of vaccination against hospitalization with COVID-19 in case of Omicron lineage, and the effectiveness in cases of more severe forms was higher than for less severe ones.

Neutralizing antibodies and cellular immune response after two doses of inactivated SARS-CoV-2 vaccine in China

The inactivated Sars-CoV-2 vaccine stimulated robust NAbs and T-cell immune responses in the first two months after the second dose but the immune effect dropped rapidly, highlighing that a third dose or additional booster immunizations may be required to boost immunity against SARS-Cov-2.

COVID-19 Vaccines Cost-Effectiveness Analysis: A Scenario for Iran

This study is a cost-effectiveness analysis utilized to calculate the incremental cost per averted disability-adjusted life year (DALY) by vaccination compared to no vaccination for different COVID-19 vaccines.



Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial.

In this prespecified interim analysis of a randomized clinical trial, treatment of adults with either of 2 inactivated SARS-CoV-2 vaccines significantly reduced the risk of symptomatic COVID-19, and serious adverse events were rare.

Age-specific mortality and immunity patterns of SARS-CoV-2

The relative risk of COVID-19-associated death for younger individuals (under 65) is consistent across countries and can be used to robustly compare the underlying number of infections in each country, and the age distribution of deaths in younger age groups is very consistent across different settings.

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

Only modest differences in vaccine effectiveness were noted with the delta variant as compared with the alpha variant after the receipt of two vaccine doses, which would support efforts to maximize vaccine uptake with two doses among vulnerable populations.

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease, and Aside from transient local and systemic reactions, no safety concerns were identified.

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older and safety over a median of 2 months was similar to that of other viral vaccines.

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

  • V. CormanO. Landt C. Drosten
  • Medicine, Biology
    Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
  • 2020
A validated diagnostic workflow for 2019-nCoV is presented, its design relying on close genetic relatedness of 2019- nCoV with SARS coronavirus, making use of synthetic nucleic acid technology.

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant.